Financial News

Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

257.93 +2.93 (+1.15%)

Streaming Delayed Price Updated: 2:14 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about AbbVie

< Previous 1 2 3 4 5 6 7 8 Next >

Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?

November 16, 2022

Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.

Via MarketBeat

Topics Intellectual Property

MarketBeat: Week in Review 10/31-11/4

November 05, 2022

You can count on MarketBeat to point you towards the stocks that are good opportunities. Here are some of the most popular articles from this week

Via MarketBeat

Topics Economy

Why is AbbVie Stock Falling, but Still Good Long-Term?

October 31, 2022

Why is AbbVie stock dropping today but still a solid investment? Its solid base, robust pipeline and dividend support a long position in ABBV stock.

Via MarketBeat

Topics Intellectual Property

As Sales of Botox and Juvederm Begin to Stall, the Abbvie Stock Price Drops

October 28, 2022

AbbVie Inc (NYSE:ABBV) AbbVie Inc (NYSE:ABBV) quarterly sales were below Wall Street’s expectations on Friday, primarily due to lower-than-anticipated income from its popular cosmetic filler Juvederm...

Via PressReach

Topics Economy

Merck Nears Breakout Point After October Surprise Good News

October 19, 2022

Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.

Via MarketBeat

Topics Stocks

Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?

October 19, 2022

JNJ stock is seen as a defensive play which has typically done well in bear markets. But there is one issue that makes longer-term forecasts uncertain

Via MarketBeat

Topics Economy

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member

September 02, 2022

Via Investor Brand Network

Topics Intellectual Property

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member

September 02, 2022

Via CannabisNewsWire

Topics Intellectual Property

Should AbbVie Inc. Have a Place in Your Dividend Portfolio?

August 26, 2022

Does AbbVie Inc. fit well into your portfolio? We'll take a look at several factors before you decide whether investing in shares makes sense for your needs.

Via MarketBeat

ABBVIE INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV

August 12, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

NYSE:ABBV Long Term Shareholder Notice: Investigation of Potential Wrongdoing at AbbVie Inc. ↗

August 10, 2022

San Diego, CA -- (SBWIRE) -- 08/10/2022 -- Certain directors of AbbVie Inc. are under investigation concerning potential breaches of fiduciary duties.

Via SBWire

Are Medtronic And Intuitive Surgical Poised For Big Growth?

August 09, 2022

Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.

Via MarketBeat

Topics ETFs

Two Appealing Biotech Stocks for Two Distinct investors

August 08, 2022

Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles

Via MarketBeat

Topics Intellectual Property

3 Pharma Stocks' Post-Earnings Price Moves

August 04, 2022

The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.

Via MarketBeat

Topics ETFs Stocks

MarketBeat: Week in Review 7/25 – 7/29

July 30, 2022

The markets are rallying as big tech earnings are lifting investors' spirits. Here are some of the stocks our analysts were looking at this week.

Via MarketBeat

Topics Artificial Intelligence Economy

Should You Buy AbbVie Ahead Of Earnings?

July 28, 2022

AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?

Via MarketBeat

MarketBeat: Week in Review 7/18 – 7/22

July 22, 2022

Investors should be careful not to read too much into this week's rally. Next week will bring the Fed's decision on interest rates and key earnings reports from the tech sector. Both could cause...

Via MarketBeat

Topics Economy

A Dose of AbbVie Stock Can Help Your Bear Market Portfolio

July 20, 2022

AbbVie (NYSE: ABBV) is a conventional stock for unconventional times. And that’s exactly why it makes sense to add or hold in your bear market portfolio.

Via MarketBeat

Topics Earnings Economy

Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

July 18, 2022

From Genmab A/S

Via Business Wire

ABBVIE INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV

July 15, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

NYSE:ABBV Long Term Shareholder Alert: Investigation of Potential Wrongdoing at AbbVie Inc. ↗

July 08, 2022

San Diego, CA -- (SBWIRE) -- 07/08/2022 -- Certain directors of AbbVie Inc. are under investigation over possible breaches of fiduciary duties.

Via SBWire

ABBVIE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of AbbVie Inc. - ABBV

June 24, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

6 Best Dividend Stocks of All Time

June 21, 2022

When you're ready to say, "Tag, you're it!" and let dividend stocks take over your portfolio, you naturally want to gravitate toward A+ companies. Luckily, you don't need to look much further than...

Via MarketBeat

Topics Economy

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Novel Drug Candidate Represents a Valuable Asset

June 15, 2022

Via Investor Brand Network

AbbVie Signs Licensing Deal With Sirona Biochem For Effective New Hydroquinone Alternative

June 15, 2022

AbbVie acquires the rights to market and commercialize Sirona’s breakthrough TFC-1067 compound AbbVie agrees to upfront, milestone, and royalty payments for patented molecules Sirona’s TFC-1067 is...

Via Zexprwire

Topics Intellectual Property

5 Pharma Company Analyst Targets and most Bullish Case for each

June 13, 2022

Via AB Newswire

Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Notifies AbbVie, Inc. (ABBV) Investors of Class Action and Last Few Hours to Actively Participate

June 06, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

ABBV FINAL DEADLINE MONDAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV

June 04, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ABBVIE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against AbbVie, Inc. and Encourages Investors to Contact the Firm

June 03, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

AbbVie (NY:ABBV)

Press Releases about AbbVie

Popular Pages